Literature DB >> 18022555

Current immunotherapeutic strategies for central nervous system tumors.

Medina C Kushen1, Adam M Sonabend, Maciej S Lesniak.   

Abstract

Immunotherapy has emerged as a promising tool in the management of malignant central nervous system tumors. Despite improvement in patient survival, traditional approaches, which consist mostly of surgery, radiotherapy, and chemotherapy, have been largely unsuccessful in permanently controlling these aggressive tumors. Immunotherapeutic strategies offer not only a novel approach but also an advantage in a way other modalities have been failing. Specifically, the capabilities of the immune system to recognize altered cells while leaving normal cells intact offer tremendous advantage over the conventional therapeutic approaches. This article summarizes our current understanding of immunotherapeutic treatment modalities used in clinical trials for management of malignant central nervous system tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022555      PMCID: PMC2173874          DOI: 10.1016/j.soc.2007.07.003

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  85 in total

Review 1.  Immune function of microglia.

Authors:  F Aloisi
Journal:  Glia       Date:  2001-11       Impact factor: 7.452

2.  Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.

Authors:  J N Parker; G Y Gillespie; C E Love; S Randall; R J Whitley; J M Markert
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

3.  Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells.

Authors:  R Yamanaka; R Tanaka; S Yoshida; T Saitoh; K Fujita; H Naganuma
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

4.  Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas.

Authors:  B H Joshi; G E Plautz; R K Puri
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

Review 5.  Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology.

Authors:  E Antonio Chiocca; William C Broaddus; George T Gillies; Therese Visted; Martine L M Lamfers
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

6.  Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

Authors:  Tetsuro Kikuchi; Yasuharu Akasaki; Toshiaki Abe; Takahiro Fukuda; Hideo Saotome; John L Ryan; Donald W Kufe; Tsuneya Ohno
Journal:  J Immunother       Date:  2004 Nov-Dec       Impact factor: 4.456

7.  Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

Authors:  T Kikuchi; Y Akasaki; M Irie; S Homma; T Abe; T Ohno
Journal:  Cancer Immunol Immunother       Date:  2001-09       Impact factor: 6.968

8.  Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12.

Authors:  Y Nishioka; M Hirao; P D Robbins; M T Lotze; H Tahara
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

Review 9.  Immune defects observed in patients with primary malignant brain tumors.

Authors:  A R Dix; W H Brooks; T L Roszman; L A Morford
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

10.  Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.

Authors:  R P Glick; T Lichtor; E de Zoeten; P Deshmukh; E P Cohen
Journal:  Neurosurgery       Date:  1999-10       Impact factor: 4.654

View more
  5 in total

Review 1.  Medulloblasoma: challenges for effective immunotherapy.

Authors:  Adam M Sonabend; Alfred T Ogden; Lisa M Maier; David E Anderson; Peter Canoll; Jeffrey N Bruce; Richard C E Anderson
Journal:  J Neurooncol       Date:  2011-12-16       Impact factor: 4.130

Review 2.  Treatment of pediatric brain tumors.

Authors:  Matthias Karajannis; Jeffrey C Allen; Elizabeth W Newcomb
Journal:  J Cell Physiol       Date:  2008-12       Impact factor: 6.384

3.  Impact of Human Immunodeficiency Virus in the Pathogenesis and Outcome of Patients with Glioblastoma Multiforme.

Authors:  Winward Choy; Carlito Lagman; Seung J Lee; Timothy T Bui; Michael Safaee; Isaac Yang
Journal:  Brain Tumor Res Treat       Date:  2016-10-31

4.  Dynamics of central and peripheral immunomodulation in a murine glioma model.

Authors:  Benjamin C Kennedy; Lisa M Maier; Randy D'Amico; Christopher E Mandigo; Elizabeth J Fontana; Allen Waziri; Marcela C Assanah; Peter Canoll; Richard C E Anderson; David E Anderson; Jeffrey N Bruce
Journal:  BMC Immunol       Date:  2009-02-18       Impact factor: 3.615

5.  Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.

Authors:  I V Ulasov; A M Sonabend; S Nandi; A Khramtsov; Y Han; M S Lesniak
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.